Efflux Pumps Contribute to Intrinsic Clarithromycin Resistance in Clinical, Mycobacterium abscessus Isolates

References

• Cowman S, van Ingen J, Griffith DE, Loebinger MR. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019;54(1):1900250. doi:10.1183/13993003.00250-201931221809
   PubMed Web of Science ®Google Scholar
• Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604–1613. doi:10.1183/09031936.0014921223598956
   PubMed Web of Science ®Google Scholar
• Lin C, Russell C, Soll B, et al. Increasing prevalence of nontuberculous mycobacteria in respiratory specimens from US-affiliated Pacific Island Jurisdictions. Emerg Infect Dis. 2018;24(3):485–491. doi:10.3201/eid2403.17130129460734
   PubMed Web of Science ®Google Scholar
• Lee H, Myung W, Koh WJ, Moon SM, Jhun BW. Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007-2016. Emerg Infect Dis. 2019;25(3):569–572. doi:10.3201/eid2503.18159730789139
   PubMed Web of Science ®Google Scholar
• Griffith DE. Mycobacterium abscessus and antibiotic resistance: same as it ever was. Clinical Infectious Diseases. 2019;69(10):1687–1689. doi:10.1093/cid/ciz07130689764
   PubMed Web of Science ®Google Scholar
• Chen J, Zhao L, Mao Y, et al. Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease. Front Microbiol. 2019;10:1977. doi:10.3389/fmicb.2019.0197731507579
   PubMed Web of Science ®Google Scholar
• Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012;67(4):810–818. doi:10.1093/jac/dkr57822290346
   PubMed Web of Science ®Google Scholar
• Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016;354(6313):751–757. doi:10.1126/science.aaf815627846606
   PubMed Web of Science ®Google Scholar
• Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl2):ii1–ii64.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi:10.1164/rccm.200604-571ST17277290
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Meier A, Brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996;40(7):1676–1681. doi:10.1128/AAC.40.7.16768807061
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tsuyuguchi K, Kobayashi T, et al. Discrepancies between the genotypes and phenotypes of clarithromycin-resistant Mycobacterium abscessus complex. Int J Tuberc Lung Dis. 2018;22(4):413. doi:10.5588/ijtld.17.067329562989
   PubMed Web of Science ®Google Scholar
• Mougari F, Bouziane F, Crockett F, et al. Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies. Antimicrob Agents Chemother. 2017;61(1). doi:10.1128/AAC.00943-16
   PubMed Web of Science ®Google Scholar
• Lipworth S, Hough N, Leach L, et al. Whole-Genome sequencing for predicting clarithromycin resistance in Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(1). doi:10.1128/AAC.00400-19
   Web of Science ®Google Scholar
• Zheng H, Liu D, Lu J, et al. Genetic correlation of antibiotic susceptibility and resistance genotyping for the Mycobacterium abscessus Group. Antimicrob Agents Chemother. 2019;63(1). doi:10.1128/AAC.00779-19
   Web of Science ®Google Scholar
• Duan W, Li X, Ge Y, et al. Mycobacterium tuberculosis Rv1473 is a novel macrolides ABC efflux pump regulated by WhiB7. Future Microbiol. 2019;14(1):47–59. doi:10.2217/fmb-2018-020730539658
   PubMed Web of Science ®Google Scholar
• Schmalstieg AM, Srivastava S, Belkaya S, et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother. 2012;56(9):4806–4815. doi:10.1128/AAC.05546-1122751536
   PubMed Web of Science ®Google Scholar
• Sharma S, Kumar M, Sharma S, Nargotra A, Koul S, Khan IA. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J Antimicrob Chemother. 2010;65(8):1694–1701. doi:10.1093/jac/dkq18620525733
   PubMed Web of Science ®Google Scholar
• Miranda-CasoLuengo AA, Staunton PM, Dinan AM, Lohan AJ, Loftus BJ. Functional characterization of the Mycobacterium abscessus genome coupled with condition specific transcriptomics reveals conserved molecular strategies for host adaptation and persistence. BMC Genomics. 2016;17. doi:10.1186/s12864-016-2868-y
   Web of Science ®Google Scholar
• Daniel J, Abraham L, Martin A, Pablo X, Reyes S. Rv2477c is an antibiotic-sensitive manganese-dependent ABC-F ATPase in Mycobacterium tuberculosis. Biochem Bioph Res Co. 2018;495(1):35–40. doi:10.1016/j.bbrc.2017.10.168
   Web of Science ®Google Scholar
• De Rossi E, Arrigo P, Bellinzoni M, et al. The multidrug transporters belonging to major facilitator superfamily (MFS) in Mycobacterium tuberculosis. Mol Med. 2002;8(11):714–724. doi:10.1007/BF340203512520088
   PubMed Web of Science ®Google Scholar
• Li XZ, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother. 2004;48(7):2415–2423. doi:10.1128/AAC.48.7.2415-2423.200415215089
   PubMed Web of Science ®Google Scholar
• Ramon-Garcia S, Martin C, Thompson CJ, Ainsa JA. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother. 2009;53(9):3675–3682. doi:10.1128/AAC.00550-0919564371
   PubMed Web of Science ®Google Scholar
• Hohl M, Remm S, Eskandarian HA, et al. Increased drug permeability of a stiffened mycobacterial outer membrane in cells lacking MFS transporter Rv1410 and lipoprotein LprG. Mol Microbiol. 2019;111(5):1263–1282. doi:10.1111/mmi.2019.111.issue-530742339
   PubMed Web of Science ®Google Scholar
• Macheras E, Roux AL, Bastian S, et al. Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (Sensu Lato) strains. J Clin Microbiol. 2011;49(2):491–499. doi:10.1128/JCM.01274-1021106786
   PubMed Web of Science ®Google Scholar
• Li B, Yang S, Chu H, et al. Relationship between Antibiotic susceptibility and genotype in Mycobacterium abscessus clinical isolates. Front Microbiol. 2017;8:1739. doi:10.3389/fmicb.2017.0173928959242
   PubMed Web of Science ®Google Scholar
• Li B, Ye M, Guo Q, et al. Determination of MIC distribution and mechanisms of decreased susceptibility to bedaquiline among clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2018;62(7). doi:10.1128/AAC.00175-18
   Web of Science ®Google Scholar
• Machado D, Couto I, Perdigao J, et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One. 2012;7:4.
   Web of Science ®Google Scholar
• Medjahed H, Singh AK. Genetic manipulation of Mycobacterium abscessus. Curr Protoc Microbiol. 2010;10:Unit 10D 12.
   Google Scholar
• Viveiros M, Dupont M, Rodrigues L, et al. Antibiotic stress, genetic response and altered permeability of E. coli. PLoS One. 2007;2(4):e365. doi:10.1371/journal.pone.000036517426813
   PubMed Web of Science ®Google Scholar
• Ramis IB, Vianna JS, Silva L, et al. In silico and in vitro evaluation of tetrahydropyridine compounds as efflux inhibitors in Mycobacterium abscessus. Tuberculosis. 2019;118:101853. doi:10.1016/j.tube.2019.07.00431430699
   PubMed Web of Science ®Google Scholar
• Ye MP, Xu LY, Zou YZ, et al. Molecular analysis of linezolid-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(2). doi:10.1128/AAC.00779-19
   Web of Science ®Google Scholar
• Guo Q, Chu HQ, Ye MP, et al. The Clarithromycin susceptibility genotype affects the treatment outcome of patients with Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2018;62(5):e02360–17.29483126
   PubMed Web of Science ®Google Scholar
• Doucet-Populaire F, Buriankova K, Weiser J, Pernodet JL. Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord. 2002;2(4):355–370.12570741
   PubMedGoogle Scholar
• Vianna JS, Ramis IB, Bierhals D, et al. Tetrahydropyridine derivative as efflux inhibitor in Mycobacterium abscessus. J Glob Antimicrob Resist. 2019;17:296–299. doi:10.1016/j.jgar.2018.12.02030630106
   PubMed Web of Science ®Google Scholar
• Wu M, Li B, Guo Q, et al. Detection and molecular characterisation of amikacin-resistant Mycobacterium abscessus isolated from patients with pulmonary disease. J Glob Antimicrob Resist. 2019;19:188–191. doi:10.1016/j.jgar.2019.05.01631121335
   PubMed Web of Science ®Google Scholar
• Vianna JS, Machado D, Ramis IB, et al. The contribution of efflux pumps in Mycobacterium abscessus complex resistance to clarithromycin. Antibiotics. 2019;8(3):153. doi:10.3390/antibiotics8030153
   Web of Science ®Google Scholar